Legal Proceedings	9 Months Ended
Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	11. Legal Proceedings On June 3, 2019, a purported federal securities class action complaint was filed against the Company, its Chief Executive Officer and Chief Financial Officer by Jimmy Wong, individually and on behalf of all others similarly situated (the “Plaintiff”), in the United States District Court for the Southern District of California (the “Complaint”). In the Complaint, the Plaintiff alleges certain violations of federal securities laws in connection with the decline in market value of the Company’s securities following the Company’s announcement of its receipt of a CRL from the FDA regarding the NDA for HTX-011. The Plaintiff seeks class action certification, damages in an unspecified amount, prejudgment and post-judgment interest, fees and costs and such other relief as the United States District Court for the Southern District of California may deem just and proper. On October 2, 2019, the United States District Court for the Southern District of California appointed lead plaintiffs and their selected counsel with respect to the matters described in the Complaint. The Company intends to defend itself vigorously in the case. Due to the early stage of this proceeding, we are not able to predict or reasonably estimate the outcome or possible losses relating to this matter.

Legal Proceedings

9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

11. Legal Proceedings

On June 3, 2019, a purported federal securities class action complaint was filed against the Company, its Chief Executive Officer and Chief Financial Officer by Jimmy Wong, individually and on behalf of all others similarly situated (the “Plaintiff”), in the United States District Court for the Southern District of California (the “Complaint”). In the Complaint, the Plaintiff alleges certain violations of federal securities laws in connection with the decline in market value of the Company’s securities following the Company’s announcement of its receipt of a CRL from the FDA regarding the NDA for HTX-011. The Plaintiff seeks class action certification, damages in an unspecified amount, prejudgment and post-judgment interest, fees and costs and such other relief as the United States District Court for the Southern District of California may deem just and proper. On October 2, 2019, the United States District Court for the Southern District of California appointed lead plaintiffs and their selected counsel with respect to the matters described in the Complaint. The Company intends to defend itself vigorously in the case. Due to the early stage of this proceeding, we are not able to predict or reasonably estimate the outcome or possible losses relating to this matter.